Iovance Biotherapeutics
3 followers
‌
Iovance Biotherapeutics (NASDAQ: IOVA) aims to improve patient care for people living with cancer. Iovance is investigating T cell-based therapies, known as tumor infiltrating lymphocytes (TIL), which use a patient’s own immune cells to attack cancer.
Industries
Headquarters
Employees
Links
Org chart
Frederick G. Vogt
Interim CEO, President & General Counsel
Frederick G. Vogt
Collapse
Friedrich Graf Finckenstein
Chief Medical Officer
Howard B. Johnson
Chief Business Officer
Brian Shew
SVP, Head of Digital & Information Technology
Tracy Winton
EVP, Human Resources
Kevin Smyth
EVP, Quality
Hequn Yin
SVP, Research
Ahmed Tawashi
Vice President, Research Alliances
Jessica Reckner
Senior Director Of Marketing
Nicholas Rojeski
Executive Director, US Marketing
Mariam Mirgoli
Senior Vice President, Data Management And Solutions
Renee Doggett
Director, Quality Control Compliance
Stefanie Bulilan
Sr. Director Quality Systems And Compliance
Asq Cqa Ulises Villavicencio
Associate Director, QA Compliance
Kerry Elizabeth Wilson Esq.
Executive Counsel
Sean Rocca
Executive Counsel
Joseph Yglesias
Manager, Next Generation Sequencing
